Payment instructions due by 31st December 2026
Sinovac Biotech Ltd. Has extended the deadline for shareholders and nominee brokers to submit payment instructions for its special cash dividend to 31st December 2026.
Sinovac trades on Nasdaq under the ticker SVA.
Eligible holders can receive US$55.00 per common share if they held valid Sinovac common shares at the close of business on 23rd May 2025 ET.
The company first set 31st December 2025 as the deadline for completed instruction materials. It then moved the date to 30th June 2026 before extending it again to 31st December 2026.
Shareholders and nominee brokers that have not yet submitted their instruction materials should do so by 31st December 2026 to facilitate payment of the dividend.
D.F. King & Co. contact details
Questions about the process can be sent to the information agent, D.F. King & Co., Inc., at 28 Liberty Street, 53rd Floor, New York, NY 10005.
The company listed the contact email as [email protected] and asked investors to use the subject line “Sinovac Biotech Ltd. Special Dividend”.
The latest extension does not change the US$55.00 payout or the 23rd May 2025 record date for eligible holders.
Sinovac Biotech Ltd. Is a China-based global biopharmaceutical company focused on vaccines and related biological products for infectious diseases.
Its portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease, poliomyelitis and pneumococcal disease.
Three vaccines have WHO prequalification: Healive®, an inactivated hepatitis A vaccine, Sabin-strain inactivated polio vaccine, or sIPV, and a varicella vaccine.
During major public health emergencies, the company was among the first to start research and development for SARS, H5N1, H1N1 and COVID-19.
It developed the world’s first inactivated SARS vaccine, which completed Phase I, and China’s first H5N1 influenza vaccine, Panflu®.
Sinovac also developed the world’s first H1N1 influenza vaccine, Panflu.1®, and CoronaVac®, the inactivated COVID-19 vaccine it said is the most widely used globally.
Beyond marketed products, the pipeline includes combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
The company is also expanding its global footprint through partnerships with research institutions and international organisations.
